Elevated Soluble Podoplanin Associates with Hypercoagulability in Patients with Nephrotic Syndrome

被引:5
|
作者
Ji, Ying [1 ]
Wang, Yan-Li [2 ]
Xu, Fang [1 ]
Jia, Xi-Bei [1 ]
Mu, Su-Hong [1 ]
Lyu, Hui-Yan [1 ]
Yuan, Xue-Ying [1 ]
Na, Shi-Ping [1 ]
Bao, Yu-Shi [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 1, Dept Nephrol, 23 Youzheng St, Harbin 150001, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Rheumatol, Harbin, Peoples R China
关键词
podoplanin; C-type lectin-like receptor 2; nephrotic syndrome; hypercoagulable state; thrombosis; VENOUS THROMBOSIS; TUMOR-METASTASIS; RECEPTOR CLEC-2; THROMBOEMBOLISM; PLATELETS; INTEGRITY; ROLES; MICE;
D O I
10.1177/10760296221108967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Podoplanin (PDPN) promotes platelet aggregation and activation by interacting with C-type lectin-like receptor 2(CLEC-2) on platelets. The interaction between the upregulated PDPN and platelet CLEC-2 stimulates venous thrombosis. PDPN was identified as a risk factor for coagulation and thrombosis in inflammatory processes. Hypercoagulability is defined as the tendency to develop thrombosis according to fibrinogen and/or D dimer levels. Nephrotic syndrome is also considered to be a hypercoagulable state. The aim of this study is to investigate the association of soluble PDPN/CLEC-2 with hypercoagulability in nephrotic syndrome. Thirty-five patients with nephrotic syndrome and twenty-seven healthy volunteers were enrolled. PDPN, CLEC-2 and GPVI concentrations were tested by enzyme-linked immunosorbent assay (ELISA). Patients with nephrotic syndrome showed higher serum levels of PDPN and GPVI in comparison to healthy controls (P < .001, P = .001). PDPN levels in patients with nephrotic syndrome were significantly correlated with GPVI (r = 0.311; P = .025), hypoalbuminemia (r = -0.735; P < .001), hypercholesterolemia (r = 0.665; P < .001), hypertriglyceridemia (r = 0.618; P < .001), fibrinogen (r = 0.606; P < .001) and D-dimer (r = 0.524; P < .001). Area under the curve (AUC) for the prediction of hypercoagulability in nephrotic syndrome using PDPN was 0.886 (95% CI 0.804-0.967, P < .001). Cut-off value for the risk probability was 5.88 ng/ml. The sensitivity of PDPN in predicting hypercoagulability was 0.806, and the specificity was 0.846. When serum PDPN was >5.88 ng/ml, the risk of hypercoagulability was significantly increased in nephrotic syndrome (OR = 22.79, 95% CI 5.92-87.69, P < .001). In conclusion, soluble PDPN levels were correlated with hypercoagulability in nephrotic syndrome. PDPN has the better predictive value of hypercoagulability in nephrotic syndrome as well as was a reliable indicator of hypercoagulable state.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] INCREASED PREVALENCE OF ELEVATED LIPOPROTEIN(A) (LP(A)) IN PEDIATRIC-PATIENTS WITH IDIOPATHIC NEPHROTIC SYNDROME (INS) COMPARED TO ADULT NEPHROTIC PATIENTS
    BROWN, CD
    IFUDU, O
    AZROLAN, N
    THOMAS, L
    ZHAO, ZH
    TEJANI, A
    FRIEDMAN, E
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1994, 5 (03): : 326 - 326
  • [22] ACTIVATED PROTEIN-C INHIBITOR - ITS PROBABLE ROLE IN HYPERCOAGULABILITY OF THE NEPHROTIC SYNDROME
    PARRAMON, I
    TIBAU, N
    OLIVER, A
    ROUSAUD, F
    CALERO, F
    DIAZ, JM
    BARCELO, P
    BALLARIN, JA
    KIDNEY INTERNATIONAL, 1991, 40 (02) : 352 - 352
  • [23] ELEVATED SERUM CREATINE-KINASE LEVELS IN DIABETIC-PATIENTS WITH THE NEPHROTIC SYNDROME
    FAUBERT, PF
    PORUSH, JG
    ANNALS OF INTERNAL MEDICINE, 1987, 107 (05) : 786 - 786
  • [24] PRODUCTION OF THE LYMPHOKINE, SOLUBLE IMMUNE-RESPONSE SUPPRESSOR (SIRS) BY PATIENTS WITH NEPHROTIC SYNDROME
    SCHNAPER, HW
    AUNE, TM
    PEDIATRIC RESEARCH, 1985, 19 (04) : A382 - A382
  • [25] SOLUBLE INTERLEUKIN-2 RECEPTOR LEVELS IN THE URINE AND PLASMA OF PATIENTS WITH NEPHROTIC SYNDROME
    SINGH, A
    NOWAKOWSKI, M
    AHMAD, H
    BALACHANDRA, S
    BAQI, N
    TEJANI, A
    PEDIATRIC RESEARCH, 1995, 37 (04) : A370 - A370
  • [26] Serum levels of soluble interleukin-2 receptor in patients with primary nephrotic syndrome
    Ayli, MD
    Duman, N
    Duranay, M
    Ates, K
    Ayli, M
    Karatan, O
    Erbay, B
    Ertug, E
    NEPHRON, 1998, 80 (03): : 349 - 350
  • [27] ELEVATED LIPOPROTEIN-(A) LEVELS IN PRIMARY NEPHROTIC SYNDROME
    FAUCHER, C
    DOUCET, C
    BAUMELOU, A
    CHAPMAN, J
    JACOBS, C
    THILLET, J
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (06) : 808 - 813
  • [28] Increased soluble leptin receptor in children with nephrotic syndrome
    Schroth, M
    Kratzsch, J
    Gröschl, M
    Rauh, M
    Rascher, W
    Dötsch, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (11): : 5497 - 5501
  • [29] Plasma levels of soluble Fas and soluble Fas ligand in children with nephrotic syndrome
    Zahra, MK
    Abu-El-Hanna, NM
    PEDIATRIC RESEARCH, 1999, 45 (05) : 772 - 772
  • [30] Plasma Levels of Soluble Fas and Soluble Fas Ligand in Children with Nephrotic Syndrome
    M K Zahra
    N M Abu-El-Hanna
    Pediatric Research, 1999, 45 : 772 - 772